NeuroPace Gestione
Criteri Gestione verificati 3/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Joel Becker
Amministratore delegato
US$2.4m
Compenso totale
| Percentuale dello stipendio del CEO | 23.56% |
| Mandato del CEO | 3yrs |
| Proprietà del CEO | 0.4% |
| Durata media del management | 1.8yrs |
| Durata media del Consiglio di amministrazione | 4.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Jun 16
NPCE: Future Returns Will Reflect IGE Decision And RNS Execution Risk
Analysts have slightly raised their NeuroPace price expectations, with a key target moving to $20 from $19 as they factor in updated revenue guidance and ongoing strength in active prescribers, accounts, and the patient pipeline. Analyst Commentary Recent commentary around NeuroPace has centered on the updated 2026 revenue outlook of US$99 million to US$101 million for the core RNS business, which implies 21% to 23% growth, and on management’s comment that this guidance does not include any potential contribution from idiopathic generalized epilepsy expansion.
Aggiornamento della narrazione • Jun 02
NPCE: Strong Prescriber Momentum And 2026 Guidance Will Support More Optimistic Outlook
Narrative Update on NeuroPace The analyst price target for NeuroPace has moved from $19 to $20. Analysts point to stronger prescriber and patient pipeline trends and higher 2026 revenue guidance for the core RNS business as key drivers of this change.Articolo di analisi • May 15
NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
It's been a sad week for NeuroPace, Inc. ( NASDAQ:NPCE ), who've watched their investment drop 18% to US$15.79 in the...Aggiornamento della narrazione • Apr 30
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have lifted their price target on NeuroPace from $15.63 to $18.00, citing updated expectations for revenue growth and profit margins, as well as a higher future P/E multiple following recent Street research coverage. Analyst Commentary The latest Street research on NeuroPace reflects constructive top line expectations alongside a watchful stance on execution and valuation risk.
Aggiornamento della narrazione • Apr 15
NPCE: Refreshed Growth Assumptions And Richer P E Outlook Will Support Upside
Analysts have increased their average price target on NeuroPace by $1, citing updated assumptions that include slightly stronger revenue growth, a revised discount rate, a lower projected profit margin and a higher future P/E multiple. Analyst Commentary Bullish analysts are highlighting NeuroPace as a name where recent research work has led to more constructive views on both execution and valuation.Aggiornamento della narrazione • Apr 01
NPCE: Higher Margin Conviction And Reaffirmed Guidance Will Support More Optimistic Outlook
Analysts have modestly increased their price target on NeuroPace by $1, citing refreshed assumptions around long term profit margins and a slightly higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see room for long term margin improvement, which supports their willingness to apply a slightly higher future P/E multiple in their models.Aggiornamento della narrazione • Mar 17
NPCE: Expanded Epilepsy Indication And Guidance Reaffirmation Will Support More Optimistic Outlook
Analysts increased their price target on NeuroPace by about $0.45 to $19.88, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target of about $19.88 as better aligned with their revised expectations for revenue growth and margin progress in the current model.Aggiornamento della narrazione • Mar 03
NPCE: Refined Risk And Margin Outlook Will Support Future Upside Potential
Analysts lifted their price target on NeuroPace by $1, citing updated assumptions around the discount rate, profit margin, and future P/E that refine how they view the company’s risk and earnings potential. Analyst Commentary Recent Street research points to a more constructive tone around NeuroPace, with bullish analysts fine tuning their models rather than making wholesale changes.Aggiornamento della narrazione • Feb 17
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have raised their price target for NeuroPace by about $1 to approximately $16, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E multiple. Analyst Commentary Even with the roughly $1 move in the price target to about $16, some research commentary still reads as cautious rather than outright bullish.Aggiornamento della narrazione • Feb 03
NPCE: Updated Seizure Trial Data Will Support A More Optimistic Outlook
Analysts have nudged their price target on NeuroPace higher to about US$19.43 from roughly US$17.13, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that are consistent with recent Street research. Analyst Commentary Analysts updating their models around NeuroPace are using the revised price target to reflect refreshed assumptions on valuation, growth expectations, and execution risks rather than a wholesale change in thesis.Aggiornamento della narrazione • Jan 20
NPCE: Broader Epilepsy Indication And Trial Evidence Will Support Future Upside
Analysts now see NeuroPace as fairly valued around US$22.00 per share. They have made only slight tweaks to assumptions for discount rate, revenue growth, profit margin and future P/E, refining rather than overhauling their previous price target view.Articolo di analisi • Jan 09
NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Aggiornamento della narrazione • Jan 06
NPCE: Expanded Epilepsy Indication And Trial Data Will Support Bullish Outlook
Analysts lifted their price target on NeuroPace from US$20.00 to US$22.00, citing changes in their fair value estimate along with updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News NeuroPace filed a Premarket Approval Supplement with the U.S. FDA to expand the labeled indication for its RNS System to antiseizure medication resistant idiopathic generalized epilepsy with generalized tonic clonic seizures, supported by preliminary NAUTILUS trial data showing a 77% median reduction in GTC seizures at 18 months and a favorable safety profile.Aggiornamento della narrazione • Dec 15
NPCE: Future Performance Will Reflect Trial Data Strength And Moderate Risk
Analysts have raised their price target on NeuroPace from 13.00 dollars to 15.00 dollars. This reflects modestly lower perceived risk, slightly stronger long term margin potential, and still supportive valuation multiples despite a tempered revenue growth outlook.Articolo di analisi • Nov 19
Revenues Tell The Story For NeuroPace, Inc. (NASDAQ:NPCE) As Its Stock Soars 25%
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 25% in the...Articolo di analisi • Sep 19
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 25% Price Jump
Those holding NeuroPace, Inc. ( NASDAQ:NPCE ) shares would be relieved that the share price has rebounded 25% in the...Articolo di analisi • Aug 14
NeuroPace, Inc. (NASDAQ:NPCE) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:NPCE 1 Year Share Price vs Fair Value Explore NeuroPace's Fair Values from the Community and select yours...Seeking Alpha • Jun 29
NeuroPace: Volatile, Uncertain, But Promising
Summary NeuroPace has shown strong sales growth in its core drug-resistant epilepsy market, but remains unprofitable due to ongoing R&D expenses. Recent topline momentum is impressive, with 2024 guidance raised and sales growth accelerating, yet operating losses have stopped narrowing and even increased. The NAUTILUS trial failed to meet primary endpoints for generalized epilepsy, a major setback that limits near-term market expansion potential. Despite a reasonable sales multiple and recent financing, the failed trial and persistent losses make me cautious and hesitant to increase my position. Read the full article on Seeking AlphaArticolo di analisi • Jun 19
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • May 13
NeuroPace, Inc. (NASDAQ:NPCE) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
NeuroPace, Inc. ( NASDAQ:NPCE ) shareholders would be excited to see that the share price has had a great month...
Nuova narrazione • Mar 30
Expanding Level 4 Epilepsy Centers Will Unlock Future Potential
Expanding presence in epilepsy centers and Project CARE may significantly boost revenue by increasing market penetration and service delivery.Articolo di analisi • Mar 07
NeuroPace, Inc. (NASDAQ:NPCE) Annual Results: Here's What Analysts Are Forecasting For This Year
It's been a sad week for NeuroPace, Inc. ( NASDAQ:NPCE ), who've watched their investment drop 11% to US$11.18 in the...Articolo di analisi • Jan 24
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 26% Price Jump
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 26% in the...Articolo di analisi • Dec 04
After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar
NeuroPace, Inc. ( NASDAQ:NPCE ) shares have had a really impressive month, gaining 90% after a shaky period beforehand...Articolo di analisi • Nov 14
Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results
A week ago, NeuroPace, Inc. ( NASDAQ:NPCE ) came out with a strong set of quarterly numbers that could potentially lead...Articolo di analisi • Nov 07
Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Aug 03
NeuroPace, Inc. (NASDAQ:NPCE) Screens Well But There Might Be A Catch
It's not a stretch to say that NeuroPace, Inc.'s ( NASDAQ:NPCE ) price-to-sales (or "P/S") ratio of 2.9x right now...Articolo di analisi • Apr 12
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 25
NeuroPace: Picking Up The Pace
Summary NeuroPace shares have doubled since September 2023, driven by strong operating momentum. The company aims to improve the lives of epilepsy patients with its remote monitoring system, which has the potential for significant growth. Following the share price rally, I have trimmed my position but continue to hold a long position due to the company's potential and operating momentum. Read the full article on Seeking AlphaArticolo di analisi • Jan 22
Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 58% in the...Articolo di analisi • Apr 17
NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company
NeuroPace, Inc. ( NASDAQ:NPCE ) shares have continued their recent momentum with a 39% gain in the last month alone...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$22m |
| Dec 31 2025 | US$2m | US$568k | -US$21m |
| Sep 30 2025 | n/a | n/a | -US$24m |
| Jun 30 2025 | n/a | n/a | -US$26m |
| Mar 31 2025 | n/a | n/a | -US$25m |
| Dec 31 2024 | US$3m | US$529k | -US$27m |
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$30m |
| Mar 31 2024 | n/a | n/a | -US$32m |
| Dec 31 2023 | US$2m | US$248k | -US$33m |
Compensazione vs Mercato: La retribuzione totale di Joel ($USD 2.41M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 2.47M ).
Compensazione vs guadagni: La retribuzione di Joel è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Joel Becker (58 yo)
3yrs
Mandato
US$2,408,567
Compensazione
Mr. Joel D. Becker serves as CEO & Director of at NeuroPace, Inc. since July 10, 2023 and serves as its President. He had been President of Cardiac Rhythm Management & Neuromodulation at Integer Holdings C...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 3yrs | US$2.41m | 0.41% $ 2.3m | |
| Chief Financial Officer | 1.1yrs | US$1.88m | Nessun dato | |
| Chief Medical Officer | 22yrs | US$1.03m | 0.15% $ 840.1k | |
| Chief of Operations & Development | 2.2yrs | Nessun dato | Nessun dato | |
| Head of Investor Relations | no data | Nessun dato | Nessun dato | |
| General Counsel & Corporate Secretary | 2.3yrs | Nessun dato | Nessun dato | |
| Vice President of Marketing | 1.5yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Sales | 1.2yrs | Nessun dato | Nessun dato | |
| Vice President of Human Resources | 1.8yrs | Nessun dato | Nessun dato | |
| VP & Controller | less than a year | Nessun dato | Nessun dato |
1.8yrs
Durata media
58yo
Età media
Gestione esperta: Il team dirigenziale di NPCE non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 3yrs | US$2.41m | 0.41% $ 2.3m | |
| Chairman of the Board | 28.7yrs | US$173.70k | 1.76% $ 9.7m | |
| Independent Director | 3.5yrs | US$126.20k | 0.054% $ 299.2k | |
| Independent Director | 1.5yrs | US$257.20k | 0.0085% $ 46.7k | |
| Independent Director | 13.5yrs | US$136.20k | 0.13% $ 711.1k | |
| Board Observer | no data | Nessun dato | Nessun dato | |
| Independent Director | 4.7yrs | US$138.70k | 0.0085% $ 46.7k | |
| Independent Director | 5.3yrs | US$138.70k | 0.068% $ 371.9k |
4.7yrs
Durata media
58yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NPCE sono considerati esperti (durata media dell'incarico 4.7 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/06 21:03 |
| Prezzo dell'azione a fine giornata | 2026/07/02 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
NeuroPace, Inc. è coperta da 13 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Michael Polark | Baird |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |